Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR(TM) (E7777) Dosing Prior to Commercial CAR?T Therapy in High?Risk Diffuse Large B?Cell Lymphoma

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR(TM)
Citius Oncology Expands International Distribution of LYMPHIR(TM) to European Union Through Exclusive Agreement with Uniphar
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.